Aida Loshaj Shala

Dr. Aida Loshaj Shala

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2022 in Annals of Neurosciences
Verified
Journal Article
Open access
GBGiangiacomo Beretta
Giangiacomo Beretta
ASAida Loshaj Shala
Aida Loshaj Shala
Background: Human neurodegenerative diseases occur as a result of various factors. Regardless of the variety in the etiology of development, many of these diseases are characterized by the accumulation of pathological, misfolded proteins; hence, such diseases are considered as proteinopathies. While plenty of research study has been conducted in order to identify the pathophysiology of these proteinopathies, there is still a lack of understanding in terms of potential therapeutic targets. Summary: Molecular chaperones present the main workforce for cellular protection and stress response. Therefore, considering these functions, molecular chaperones present a promising target for research within the field of conformational diseases that arise from proteinopathies. Since the association between neurodegenerative disorders and their long-term consequences is well documented, the need for the development of new therapeutic strategies becomes even more critical Key message: In this review, we summarized the molecular function of heat shock proteins and recent progress on their role, involvement, and other mechanisms related to neurodegeneration caused by different etiological factors. Based on the relevant scientific data, we will highlight the functional classification of heat shock proteins, regulation, and their therapeutic potential for neurodegenerative disorders.

16 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ASAida Loshaj Shala
Aida Loshaj Shala
Ilaria ArduinoIlaria Arduino
Ilaria Arduino
MBMimoza Basholli-Salihu
Mimoza Basholli-Salihu
Nunzio DenoraNunzio Denora
Nunzio Denora
The development of efficient treatments for tumors affecting the central nervous system (CNS) remains an open challenge. Particularly, gliomas are the most malignant and lethal form of brain tumors in adults, causing death in patients just over 6 months after diagnosis without treatment. The current treatment protocol consists of surgery, followed using synthetic drugs and radiation. However, the efficacy of these protocols is associated with side effects, poor prognosis and with a median survival of fewer than two years. Recently, many studies were focused on applying plant-derived products to manage various diseases, including brain cancers. Quercetin is a bioactive compound derived from various fruits and vegetables (asparagus, apples, berries, cherries, onions and red leaf lettuce). Numerous in vivo and in vitro studies highlighted that quercetin through multitargeted molecular mechanisms (apoptosis, necrosis, anti-proliferative activity and suppression of tumor invasion and migration) effectively reduces the progression of tumor cells. This review aims to summarize current developments and recent advances of quercetin’s anticancer potential in brain tumors. Since all reported studies demonstrating the anti-cancer potential of quercetin were conducted using adult models, it is suggested to expand further research in the field of paediatrics. This could offer new perspectives on brain cancer treatment for paediatric patients.

8 April 2025 in Journal of Research in Pharmacy
Verified
Journal Article
Open access
PDF file
MSMimoza Basholli Salihu
Mimoza Basholli Salihu
EHEntela Haloci
Entela Haloci
TKToskë Kryeziu
Toskë Kryeziu
JAJehona Ahmeti
Jehona Ahmeti
BZBlerta Zogjani
Blerta Zogjani
ASAida Loshaj Shala
Aida Loshaj Shala
This research focuses on the assessment of cytotoxic and antimicrobial properties of Thymus capitatus essential oil (TEO) and Origanum vulgare essential oil (OEO), before and after encapsulation in nanoemulsions, prepared utilizing high-pressure homogenization. These plants, indigenous to northern Albania and Mediterranean regions, produce EO with notable biological and cytotoxic activities. However, volatility, poor solubility, and chemical instability limit their practical application. Incorporating these oils into NE aims to enhance their stability and biological activity. The antimicrobial efficacy of the EO exhibited variability against different strains, showing particular effectiveness against E. coli ATCC 25922, S. aureus ATCC 29213, and C. albicans ATCC 10231, with no effect was observed against P. aeruginosa ATCC 27853. The EO-loaded NE exhibited enhanced cytotoxicity against MCF7, DU 145, and HT-29 cancer cell lines compared to the free oil. Encapsulation was found to augment the bioactivity of these volatile oils, with TEO-NE demonstrating superior cytotoxic effects than OEO-NE. Following encapsulation, OEO exhibited superior antimicrobial efficacy relative to TEO against S. aureus, E. coli, and C. albicans. Our results suggest that NE may enhance the cytotoxic and antimicrobial potential of the EOs, in different manner among EO used. The encapsulation of TEO and OEO in NE shows promising therapeutic potential, although further studies are required. However, these conclusions are drawn from in vitro analyses, underscoring the need for subsequent in vivo studies to ascertain this innovative clinical safety and efficacy.

12 November 2026 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Closed access
PDF file
ASAida Loshaj Shala
Aida Loshaj Shala
ENErza Nikqi
Erza Nikqi
BBBrikena Bilalli
Brikena Bilalli
TKToskë Kryeziu
Toskë Kryeziu
GRGiorgio Reggiardo
Giorgio Reggiardo
MBMimoza Basholli-Salihu
Mimoza Basholli-Salihu

27 October 2026 in Pharmacia
Verified
Journal Article
Open access
PDF file
VLVenesa Lupçi
Venesa Lupçi
ASAida Loshaj Shala
Aida Loshaj Shala
ALAnita Lupçi
Anita Lupçi
UBUfuk Bagci
Ufuk Bagci
MBMimoza Basholli-Salihu
Mimoza Basholli-Salihu
TKToskë Kryeziu
Toskë Kryeziu
A structured narrative review examined how vesicle composition, size, charge, surface modification, and aerosolization affect pulmonary delivery and used the findings to construct an operational formulation decision framework. PubMed was searched for English-language publications from 2021 to September 2026, with targeted searches of publisher and regulatory sources. Selection was non-systematic and relevance-based, without a formal risk-of-bias assessment; 62 sources were graded according to a four-level hierarchy. Several framework elements—aerosol stability, PEG-lipid effects, and nucleic acid delivery—rely partly on non-liposomal comparators, requiring confirmation in conventional liposomes. The framework is an eight-step decision matrix linking therapeutic objective, deposition region, dominant barrier, formulation variables, aerosol platform, and verification readouts, applied to four disease contexts. Smaller or PEGylated vesicles may improve mucus transport, but PEGylation can reduce cellular uptake and alter surfactant interactions; nebulization and drying may compromise vesicle integrity. Amikacin liposome inhalation suspension remains the principal clinical precedent. The approach supports hypothesis-driven selection but requires prospective validation.

5 September 2025
Verified
Book Chapter
Closed access
ASAida Loshaj Shala
Aida Loshaj Shala
TKToskë Kryeziu
Toskë Kryeziu
DFDafina Fondaj
Dafina Fondaj
NDNunzio Denora
Nunzio Denora
MSMimoza Basholli Salihu
Mimoza Basholli Salihu
Glioblastoma (GBM) is among the most aggressive and therapy-resistant brain tumors, due to its invasive growth, heterogeneity, and limited response to standard treatments. This chapter reviews GBM pathology, including molecular features, glioma-initiating cells, hypoxia, and challenges posed by the blood–brain barrier (BBB). It explores nanotechnology-based strategies—liposomes, micelles, dendrimers, solid lipid, and biomimetic nanoparticles—focused on targeting, uptake, drug release, and BBB penetration. Preclinical studies show improved biodistribution and tumor accumulation. Clinical trials with liposomal doxorubicin and irinotecan show modest outcomes, underscoring a gap in clinical translation. The chapter highlights the need for improved delivery systems and personalized approaches. Nanotechnology offers promising potential for advancing GBM therapy.